Immunotherapy

Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab

Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab

By

A significantly higher 5-year survival rate was seen in a small subset of patients with NSCLC treated with nivolumab.

Continuing Nivolumab After Progression of Head and Neck Cancer May Improve Survival

Continuing Nivolumab After Progression of Head and Neck Cancer May Improve Survival

By

Continuing immunotherapy after disease progression extends survival for some patients with head and neck cancer.

Prostate Cancer Response to Immunotherapy Improved With Combination Therapy

Prostate Cancer Response to Immunotherapy Improved With Combination Therapy

By

Immunotherapy alone is not effective in prostate cancer; however, combining it with PD-1/PD-L1 and VISTA inhibitors is effective.

Research Shows iPS-ML/IFN-β Migrates to, Penetrate Liver Cancer Tumors

Research Shows iPS-ML/IFN-β Migrates to, Penetrate Liver Cancer Tumors

By

Decreased liver tumor growth and improved survival in a mouse model were noted after injecting iPS-ML/IFN-β.

Pembrolizumab May Help Combat Mesothelioma

Pembrolizumab May Help Combat Mesothelioma

By

Checkpoint inhibitor pembrolizumab appears well-tolerated with antitumor activity in patients with malignant pleural mesothelioma.

Genome Sequencing Explains Resistance to CTLA-4 and PD-1 Inhibitors in Metastatic Melanoma

Genome Sequencing Explains Resistance to CTLA-4 and PD-1 Inhibitors in Metastatic Melanoma

By

Whole-exome sequencing of tumor biopsies explain low response rate to immunotherapy in metastatic melanoma.

Cabozantinib Activates Innate Immune Response, Eliminating Prostate Cancer

Cabozantinib Activates Innate Immune Response, Eliminating Prostate Cancer

By

Cabozantinib activated innate immunity and completely eradicated prostate cancer in a study using a mouse model.

Regorafenib Improves Quality-adjusted Survival in Sarcoma

Regorafenib Improves Quality-adjusted Survival in Sarcoma

By

In patients with soft tissue sarcoma pretreated with doxorubicin, treatment with regorafenib significantly reduced the risk of progression symptoms or toxicity.

Immunosuppressor Inhibits Metabolic Pathway in Breast Cancer, Kills Cancer Cells

Immunosuppressor Inhibits Metabolic Pathway in Breast Cancer, Kills Cancer Cells

By

Leflunomide, an immunosuppressor FDA-approved for rheumatoid arthritis, is effective against breast cancer in mouse study.

PI3K/mTOR Inhibitor Demonstrates Efficacy in Some Uterine Sarcomas

PI3K/mTOR Inhibitor Demonstrates Efficacy in Some Uterine Sarcomas

By

A new generation dual PI3K/mTOR inhibitor shows promise in treating leiomyosarcomas with the protein P-S6S240.

Dabrafenib + Trametinib Rechallenge Active in Pretreated Melanoma

Dabrafenib + Trametinib Rechallenge Active in Pretreated Melanoma

By

Rechallenge with dabrafenib plus trametinib demonstrated antitumor activity in patients who had previously progressed on BRAF inhibitor therapy.

Patients With HER2-enriched Subtype Benefit Most from Dual HER2 Blockade

Patients With HER2-enriched Subtype Benefit Most from Dual HER2 Blockade

By

HER-2 enriched subtype predicts for HER2 blockade benefit with lapatinib and trastuzumab

Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated

Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated

By

Researchers sought to conduct a cost-effectiveness analysis of immunotherapy for patients with advanced melanoma.

1 Year of Adjuvant Trastuzumab Improves Long-Term DFS in Early Breast Cancer

1 Year of Adjuvant Trastuzumab Improves Long-Term DFS in Early Breast Cancer

By

Adjuvant trastuzumab following chemotherapy significantly improves long-term disease-free survival in women with HER2-positive early breast cancer, according to study data.

Immunotherapy and the Future of Prostate Cancer Treatment

Immunotherapy and the Future of Prostate Cancer Treatment

By

Despite early failures, there may be a role for single-agent and combination immunotherapy for patients with prostate cancer.

Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

By

In a study seeking new therapies to improve outcomes for patients with relapsed or refractory CLL, researchers investigated the impact on progression-free survival of adding idelalisib to bendamustine plus rituximab.

Attaching an Anticancer Payload to Platelets Shows Promise Against Postsurgical Recurrence

Attaching an Anticancer Payload to Platelets Shows Promise Against Postsurgical Recurrence

By

Researchers develop novel strategy for delivering immunotherapy agents to tumor surgical sites to eradicate tumor cells left behind after resection and reduce risk of recurrence.

Addition of Bevacizumab to Chemo Improves PFS in Extensive SCLC

Addition of Bevacizumab to Chemo Improves PFS in Extensive SCLC

By

The addition of bevacizumab to first-line treatment with cisplatin plus etoposide improved PFS, but not OS, with an acceptable toxicity profile in patients with extensive-disease SCLC.

New Targeted Therapy with a Double-Pronged Approach

New Targeted Therapy with a Double-Pronged Approach

By

A new targeted therapy approach may attack cancer on two fronts, boosting anti-tumor immune responses while also directly killing tumor cells .

New Use of an Old Drug Could Address Cancer Metastasis

New Use of an Old Drug Could Address Cancer Metastasis

By

CDK 4/6 inhibitors, currently approved for the treatment of estrogen-positive breast cancer, were found to inhibit metastasis in triple-negative breast

MABp1 Improves Symptoms vs Placebo in Colorectal Cancer

MABp1 Improves Symptoms vs Placebo in Colorectal Cancer

By

MABp1 (Xilonix) is an interleukin 1α-targeting antibody associated with antitumor activity and relief of debilitating symptoms in patients with advanced colorectal cancer. In this ongoing phase 3 clinical trial, its impact on other debilitating symptoms in this population was evaluated.

Diarrhea Common But Manageable With Pertuzumab-containing Regimens

Diarrhea Common But Manageable With Pertuzumab-containing Regimens

By

Because treatment with pertuzumab could include adverse events similar to those observed with EGFR antagonists, such as diarrhea, researchers evaluated participants from 3 trials to determine the incidence and severity of diarrhea observed with pertuzumab.

O-DHAP and R-DHAP Equivalent As Salvage Therapy for R/R DLBCL

O-DHAP and R-DHAP Equivalent As Salvage Therapy for R/R DLBCL

By

Researchers sought to compare the efficacy of O-DHAP with R-DHAP as salvage treatment, followed by autologous hematopoietic cell transplantation.

Topical Combination Reduces Actinic Keratosis Lesions, Reducing Risk of Squamous Cell Carcinoma

Topical Combination Reduces Actinic Keratosis Lesions, Reducing Risk of Squamous Cell Carcinoma

By

Study investigates the effectiveness of a topical treatment with an immune system-activator and a topical chemotherapy on actinic keratosis, a precursor to squamous cell carcinoma.

Atezolizumab Prolongs Survival vs Docetaxel in Previously Treated NSCLC

Atezolizumab Prolongs Survival vs Docetaxel in Previously Treated NSCLC

By

The efficacy and safety of atezolizumab in patients with previously treated NSCLC was evaluated in the OAK trial, an open-label, pivotal, phase 3 study, the results of which were recently published.

Survival Not Better With Onartuzumab Plus Erlotinib for MET-Positive NSCLC

Survival Not Better With Onartuzumab Plus Erlotinib for MET-Positive NSCLC

By

Results of the METLung trial are presented. In this trial, researchers evaluated the efficacy and safety of onartuzumab in patients with advanced NSCLC selected by MET immunohistochemistry.

Panitumumab Plus Accelerated RT Not Effective for Locoregionally Advanced HNSCC

Panitumumab Plus Accelerated RT Not Effective for Locoregionally Advanced HNSCC

By

Progression-free survival with panitumumab plus accelerated-fractionation radiotherapy was compared with that of cisplatin plus standard-fractionation radiotherapy in patients with locoregionally advanced HNSCC in a recently published study.

Dual HER2 Blockade With an AI Effective in Advanced Breast Cancer

Dual HER2 Blockade With an AI Effective in Advanced Breast Cancer

By

Patients with HER2-positive, HR-positive advanced breast cancer experience significantly improved progression-free survival when pertuzumab is added to first-line trastuzumab and an AI compared with trastuzumab and an AI alone, according to study findings presented at SABCS 2016.

Study Identifies Factors Associated With Outcomes After Dabrafenib + Trametinib

By

Despite the effectiveness of dabrafenib in combination with trametinib for metastatic BRAF-mutant melanoma, many patients experience disease progression that often leads to death. In this data analysis, researcher sought to identify clinical factors associated with long-term response and survival.

PD-1 Inhibitors Ideal for First-Line Therapy in Treatment-Naïve Advanced Melanoma

PD-1 Inhibitors Ideal for First-Line Therapy in Treatment-Naïve Advanced Melanoma

By

Atlhough survival for patients with advanced melanoma is similar with both targeted therapies and immunotherapies, a review of the literature reveals why one of them may be a better choice as first-line therapy.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs